retatrutide mechanism gip glp-1 glucagon triple agonist 🚨 HOT OFF THE PRESS: Phase 3 data has arrived — and the obesity medicine world is paying attention. In Lilly's TRIUMPH-1 trial, participants receiving the highest dose achieved an average Demonstrated metabolic effects of GIP,

GLP-1 has multiple beneficial effects in cardiovascular diseases such as hypertension, myocardial ischemia, atherosclerosis, and heart failure

Atherosclerotic CVD manifest as heart attacks and strokes, is responsible for up to 85 per cent of cardiovascular deaths [1]

Matrix metalloproteinase-9 delays wound healing in a murine wound model

In other words, they help food leave the stomach more slowly

Research from 2021 suggests that dietary changes promoting the bodys natural release of GLP-1 could be useful for managing obesity and type 2 diabetes

[PubMed] [Google Scholar] 14.Gke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J